All In Biotech

Drug Trial Radar · NCT07265622

First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors

A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of 7MW4911 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 12, 2025

Primary completion

Jul 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Dec 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the first-in-human study of 7MW4911 in Chinese patients, to investigate its prelimary safety and efficacy in patients with Advanced Solid Tumors.

Conditions

  • Solid Tumors

Interventions

  • 7MW4911Drug

    7MW4911 for IV infusion of various dose strengths administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and rates of adverse eventsTime frame: Up to approximately 2 years
  2. Maximum tolerated dose (MTD), recommended expansion dose (RED) and the recommended phase II dose (RP2D)Time frame: Up to approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.